Skip to main content
Log in

Association Between Platelet Glycoprotein IIb/IIIa Inhibition and In-Hospital Outcomes in ST-Elevation Myocardial Infarction Patients Treated with Coronary Thrombus Aspiration: Findings from the CCC-ACS Project

  • Original Article
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Purpose

Thrombus aspiration in ST-elevation myocardial infarction (STEMI) with high thrombus burden did not improve clinical outcomes. The clinical efficacy of the bailout use of platelet glycoprotein IIb/IIIa inhibitors (GPIs) in this clinical scenario remains unknown.

Methods

We assessed associations between GPI use and in-hospital major bleeds, ischemic events, and mortality among STEMI patients treated with percutaneous coronary intervention (PCI) and thrombus aspiration in a nationwide acute coronary syndrome registry (the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome project).

Results

A total of 5896 STEMI patients who received thrombus aspiration were identified, among which 56.3% received GPI therapy. In a 1-to-1 propensity-score-matched cohort, compared with STEMI patients not treated with GPI, GPI use was associated with a 69% increase in major in-hospital bleeds, with an odds ratio (OR) of 1.69, a 95% confidence interval (CI) of 1.08 to 2.65, and a nonsignificant reduction in ischemic events (OR: 0.61, 95% CI: 0.36 to 1.06), as well as a neutral effect on mortality (OR: 0.93, 95% CI: 0.55 to 1.58). However, among patients aged < 60 years, GPI use was associated with a reduction in ischemic events (OR: 0.27, 95% CI: 0.08 to 0.98), and no significant increase in major bleeds was observed.

Conclusion

In a nationwide registry, routine use of GPI following thrombus aspiration was not associated with reduced in-hospital ischemic events and mortality but at the cost of increased major bleeding. However, for patients aged < 60 years, there may be a potential net benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data Availability

Not applicable.

Code Availability

Not applicable.

References

  1. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists’ view. Eur Heart J. 2013;34:719–28.

    Article  CAS  PubMed  Google Scholar 

  2. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.

    Article  PubMed  Google Scholar 

  3. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. 2015 ACC/AHA/SCAI Focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2016;67:1235–50.

    Article  PubMed  Google Scholar 

  4. Montalto C, Kotronias RA, Marin F, Terentes-Printzios D, Shanmuganathan M, Emfietzoglou M, Scalamera R, Porto I, Langrish J, Lucking A, et al. Pre-procedural ATI score (age-thrombus burden-index of microcirculatory resistance) predicts long-term clinical outcomes in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Int J Cardiol. 2021;339:1–6.

    Article  PubMed  Google Scholar 

  5. Jolly SS, James S, Džavík V, Cairns JA, Mahmoud KD, Zijlstra F, Yusuf S, Olivecrona GK, Renlund H, Gao P, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: an individual patient meta-analysis: thrombectomy trialists collaboration. Circulation. 2017;135:143–52.

    Article  PubMed  Google Scholar 

  6. [2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47:766–783.

  7. Chang K, Ahn Y, Lim S, Yang JH, Lee KY, Choo EH, Kim HK, Nam CW, Kim W, Hwang JY, et al. 2021 Korean society of myocardial infarction expert consensus document on revascularization for acute myocardial infarction. Korean Circ J. 2021;51:289–307.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Li YH, Lee CH, Huang WC, Wang YC, Su CH, Sung PH, Chien SC, Hwang JJ. 2020 Focused Update of the 2012 Guidelines of the Taiwan society of cardiology for the management of ST-segment elevation myocardial infarction. Acta Cardiol Sin. 2020;36:285–307.

    PubMed  PubMed Central  Google Scholar 

  9. Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, Sakamoto T, Tsujita K, Hagiwara N, Miyazaki S, et al. JCS 2018 Guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83:1085–196.

    Article  CAS  PubMed  Google Scholar 

  10. Kim HK, Tantry US, Smith SC Jr, Jeong MH, Park SJ, Kim MH, Lim DS, Shin ES, Park DW, Huo Y, et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost. 2021;121:422–32.

    Article  PubMed  Google Scholar 

  11. Wu JH, Hao PP, Chen YG, Li RJ. Intracoronary glycoprotein IIb/IIIa inhibitors improve short-term mortality and reinfarction in East Asian patients with ST-segment elevation myocardial infarction after thrombus aspiration: a meta-analysis. Evid Based Complement Alternat Med. 2018;2018:5174714.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Zheng C, Kang J, Yang HM, Han JK, Park KW, Kang HJ, Koo BK, Kim HS. Safety and efficacy of glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction in the presence of intracoronary thrombus: an analysis from the grand drug-eluting stent registry. Clin Ther. 2020;42:954-958.e956.

    Article  CAS  PubMed  Google Scholar 

  13. Hao Y, Liu J, Liu J, Smith SC Jr, Huo Y, Fonarow GC, Ma C, Ge J, Taubert KA, Morgan L, et al. Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: a national effort to prompt quality enhancement for acute coronary syndrome. Am Heart J. 2016;179:107–15.

    Article  PubMed  Google Scholar 

  14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Choudry FA, Hamshere SM, Rathod KS, Akhtar MM, Archbold RA, Guttmann OP, Woldman S, Jain AK, Knight CJ, Baumbach A, et al. High thrombus burden in patients With COVID-19 presenting with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2020;76:1168–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Jolly SS, Cairns JA, Lavi S, Cantor WJ, Bernat I, Cheema AN, Moreno R, Kedev S, Stankovic G, Rao SV, et al. Thrombus aspiration in patients with high thrombus burden in the TOTAL Trial. J Am Coll Cardiol. 2018;72:1589–96.

    Article  PubMed  Google Scholar 

  17. Crea F, Camici PG, BaireyMerz CN. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35:1101–11.

    Article  PubMed  Google Scholar 

  18. Alexopoulos D, Xanthopoulou I, Tsigkas G, Damelou A, Theodoropoulos KC, Makris G, Gizas V, Kassimis G, Davlouros P, Hahalis G. Intrinsic platelet reactivity and thrombus burden in patients with ST-elevation myocardial infarction. Thromb Res. 2013;131:333–7.

    Article  CAS  PubMed  Google Scholar 

  19. Huang D, Qian J, Liu Z, Xu Y, Zhao X, Qiao Z, Fang W, Jiang L, Hu W, Shen C, et al. Effects of intracoronary pro-urokinase or tirofiban on coronary flow during primary percutaneous coronary intervention for acute myocardial infarction: a multi-center, placebo-controlled, single-blind, randomized clinical trial. Front Cardiovasc Med. 2021;8: 710994.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Mahmoud KD, Zijlstra F. Thrombus aspiration in acute myocardial infarction. Nat Rev Cardiol. 2016;13:418–28.

    Article  PubMed  Google Scholar 

  21. Zhou SS, Tian F, Chen YD, Wang J, Sun ZJ, Guo J, Jin QH. Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction. J Geriatr Cardiol. 2015;12:135–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm C, Price MJ, Prats J, Elkin S, et al. Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: an analysis from the CHAMPION PHOENIX trial. Int J Cardiol. 2019;278:217–22.

    Article  PubMed  Google Scholar 

  23. Velibey Y, Guvenc TS, Demir K, Oz A, Akdeniz E, Guvenc RC, Guzelburc O, Yildiz U, Safak A, Kalenderoglu K, et al. Effects of bailout tirofiban on in-hospital outcomes and long-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Angiology. 2019;70:431–9.

    Article  CAS  PubMed  Google Scholar 

  24. Li L, Geraghty OC, Mehta Z, Rothwell PM. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390:490–9.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556–66.

    Article  PubMed  Google Scholar 

  26. Mathews R, Peterson ED, Chen AY, Wang TY, Chin CT, Fonarow GC, Cannon CP, Rumsfeld JS, Roe MT, Alexander KP. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. Am J Cardiol. 2011;107:1136–43.

    Article  PubMed  Google Scholar 

  27. Andreotti F, Rocca B, Husted S, Ajjan RA, Ten Berg J, Cattaneo M, Collet JP, De Caterina R, Fox KA, Halvorsen S, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on thrombosis. Eur Heart J. 2015;36:3238–49.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The article was written on behalf of the CCC-ACS project investigators.

Funding

This work was supported by a collaborative program of the American Heart Association and the Chinese Society of Cardiology. The American Heart Association was funded by Pfizer and AstraZeneca for the quality improvement initiative through an independent grant for learning and change. This work was also supported by the National Key R&D Program of China (Nos. 2020YFC2004700, 2020YFC2004706), Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-069C), and Tianjin Municipal Science and Technology Commission (19JCQNJC11500).

Author information

Authors and Affiliations

Authors

Consortia

Contributions

XZ, QY, and YL conceived and designed the study, supervised the analysis process, interpreted the data, and revised the manuscript. WL and ZL analyzed the data and drafted the manuscript. WL, ZL, TY, GA, HS, HL, XS, ZJ, and LL helped to analyze the data and table and figure generation. YH, JL, and DZ supervised the CCC-ACS project and interpreted the data. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Xin Zhou or Qing Yang.

Ethics declarations

Ethics Approval

The CCC-ACS project was approved by the institutional review board of Beijing Anzhen Hospital, Capital Medical University, with a waiver for informed consent.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

A complete list of CCC-ACS investigators is given at the Supplemental Table 11.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 206 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, W., Li, Z., Yang, T. et al. Association Between Platelet Glycoprotein IIb/IIIa Inhibition and In-Hospital Outcomes in ST-Elevation Myocardial Infarction Patients Treated with Coronary Thrombus Aspiration: Findings from the CCC-ACS Project. Cardiovasc Drugs Ther 38, 315–325 (2024). https://doi.org/10.1007/s10557-022-07398-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-022-07398-w

Keywords

Navigation